STRATEC Biomedical (SBS) Stock Statistics & Valuation Metrics

STRATEC Biomedical has a market cap or net worth of €203.73M. The enterprise value is €296.97M.

STRATEC Biomedical has 12,157,841 shares outstanding. The number of shares has decreased by -2.65% in one year.

STRATEC Biomedical’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.10%.

The current PE Ratio of STRATEC Biomedical is ―. STRATEC Biomedical’s PEG ratio is 11.11.

In the last 12 months, STRATEC Biomedical had revenue of 250.86M and earned -242.00K in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -433.00K and capital expenditures -11.07M, giving a free cash flow of -11.50M billion.

STRATEC Biomedical pays an annual dividend of €0.6, resulting in a dividend yield of 2.71%

STRATEC Biomedical upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).

STRATEC Biomedical as a current ratio of 3.97, with Debt / Equity ratio of ―

In the past 12 months, STRATEC Biomedical has paid 5.09M in taxes.

STRATEC Biomedical EV to EBITDA ratio is 14.05, with an EV/FCF ratio of -39.33.

STRATEC Biomedical has €23.06M in cash and marketable securities with €116.97M in debt, giving a net cash position of -€109.08M billion.

Gross margin is ―, with operating margin of 3.43%, and net profit margin of -0.10%.

The average price target for STRATEC Biomedical is €29.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy